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Summary
Background The eﬀ ects of extra-pleural pneumonectomy (EPP) on survival and quality of life in patients with 
malignant pleural mesothelioma have, to our knowledge, not been assessed in a randomised trial. We aimed to assess 
the clinical outcomes of patients who were randomly assigned to EPP or no EPP in the context of trimodal therapy in 
the Mesothelioma and Radical Surgery (MARS) feasibility study.
Methods MARS was a multicentre randomised controlled trial in 12 UK hospitals. Patients aged 18 years or older who 
had pathologically conﬁ rmed mesothelioma and were deemed ﬁ t enough to undergo trimodal therapy were included. 
In a prerandomisation registration phase, all patients underwent induction platinum-based chemotherapy followed 
by clinical review. After further consent, patients were randomly assigned (1:1) to EPP followed by postoperative 
hemithorax irradiation or to no EPP. Randomisation was done centrally with computer-generated permuted blocks 
stratiﬁ ed by surgical centre. The main endpoints were feasibility of randomly assigning 50 patients in 1 year (results 
detailed in another report), proportion randomised who received treatment, proportion eligible (registered) who 
proceeded to randomisation, perioperative mortality, and quality of life. Patients and investigators were not masked to 
treatment allocation. This is the principal report of the MARS study; all patients have been recruited. Analyses were 
by intention to treat. This trial is registered, number ISRCTN95583524.
Findings Between Oct 1, 2005, and Nov 3, 2008, 112 patients were registered and 50 were subsequently randomly 
assigned: 24 to EPP and 26 to no EPP. The main reasons for not proceeding to randomisation were disease progression 
(33 patients), inoperability (ﬁ ve patients), and patient choice (19 patients). EPP was completed satisfactorily in 16 of 
24 patients assigned to EPP; in ﬁ ve patients EPP was not started and in three patients it was abandoned. Two patients 
in the EPP group died within 30 days and a further patient died without leaving hospital. One patient in the no EPP 
group died perioperatively after receiving EPP oﬀ  trial in a non-MARS centre. The hazard ratio [HR] for overall 
survival between the EPP and no EPP groups was 1·90 (95% CI 0·92–3·93; exact p=0·082), and after adjustment for 
sex, histological subtype, stage, and age at randomisation the HR was 2·75 (1·21–6·26; p=0·016). Median survival 
was 14·4 months (5·3–18·7) for the EPP group and 19·5 months (13·4 to time not yet reached) for the no EPP group. 
Of the 49 randomly assigned patients who consented to quality of life assessment (EPP n=23; no EPP n=26), 12 patients 
in the EPP group and 19 in the no EPP group completed the quality of life questionnaires. Although median quality 
of life scores were lower in the EPP group than the no EPP group, no signiﬁ cant diﬀ erences between groups were 
reported in the quality of life analyses. There were ten serious adverse events reported in the EPP group and two in 
the no EPP group.
Interpretation In view of the high morbidity associated with EPP in this trial and in other non-randomised studies a 
larger study is not feasible. These data, although limited, suggest that radical surgery in the form of EPP within 
trimodal therapy oﬀ ers no beneﬁ t and possibly harms patients.
Funding Cancer Research UK (CRUK/04/003), the June Hancock Mesothelioma Research Fund, and Guy’s and 
St Thomas’ NHS Foundation Trust.
Introduction
At a time when deaths from malignant pleural 
mesothelioma were rising in the UK1,2 and Europe,3 data 
from the UK Thoracic Surgical Register of the Society for 
Cardiothoracic Surgery in Great Britain and Ireland 
showed that few patients were being oﬀ ered surgery for 
their disease. Encouraging results from large case series 
had been reported for extrapleural pneumonectomy 
(EPP),4–7 in which the lung and ipsilateral parietal pleura, 
pericardium, and hemidiaphragm are resected. In some 
institutions, this procedure, within a multimodal 
treatment regimen, became the standard of care in the 
management of patients with resectable malignant 
pleural mesothelioma.
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In 2004, we did a systematic review to assess the 
available evidence for eﬀ ectiveness of EPP.8 Median 
survival ranged from 17 to 35 months in seven surgical 
follow-up studies reported from 1999 to 2004. The 
available data had been reported retrospectively on the 
basis of completed treatment and so measurement of 
the extent to which survival was inﬂ uenced by EPP itself 
rather than the initial selection of treatment and 
subsequent progressive selection for continued 
treatment in patients with a favourable prognosis was 
not possible.
To establish the eﬃ  cacy of EPP, we designed the 
Mesothelioma and Radical Surgery (MARS) trial.9 EPP, 
within the context of trimodal therapy, was to be 
compared with induction chemotherapy but no EPP. At 
the start of the trial, a power calculation, on the basis of 
the diﬀ erence claimed for eﬀ ectiveness of EPP8 and 
natural history data,10 suggested that 670 patients would 
be needed to identify any statistically signiﬁ cant 
diﬀ erence between EPP and no EPP with overall 
survival as the primary outcome. Because of the 
anticipated diﬃ  culty in recruiting patients, an initial 
feasibility study was done with the objective of 
randomising 50 patients within 1 year to EPP or no EPP 
to assess patient acceptability and to gauge the potential 
recruitment rate that could be expected in a larger trial. 
Randomisation between groups was possible but took 
longer than would be feasible to recruit suﬃ  cient 
numbers to a deﬁ nitive trial.11 Here we report the 
survival and quality of life outcomes of MARS 2 years 
after recruitment was completed.
Methods
Patients
The MARS feasibility study was a multicentre randomised 
controlled trial with a prerandomisation registration phase 
and a two-stage consent process (ﬁ gure 1). 12 UK hospitals 
took part in the study. Patients provided written informed 
consent before registration, after which they had surgical 
staging by cervical mediastinoscopy and, where available, 
PET. After staging, patients had three cycles of platinum-
based chemotherapy with a regimen chosen by the treating 
physician at the local centre. Regimens suggested by the 
trial management group included mitomycin, vinblastine, 
and cisplatin; cisplatin and gemcitabine; or cisplatin and 
pemetrexed. Patients were informed that further written 
consent for randomisation between EPP or no EPP might 
be requested when they had completed chemotherapy and 
been reassessed clinically. Patients were eligible for 
registration if they were aged 18 years or older with 
pathologically conﬁ rmed mesothelioma and no evidence 
on preoperative CT staging of unresectable disease or 
distant metastases. They also had to be deemed ﬁ t enough 
to undergo preoperative chemotherapy followed by 
pneumonectomy (according to British Thoracic Society 
criteria for lung cancer surgery)12 and the planned 
postoperative radiotherapy.
After chemotherapy, patients underwent restaging by 
CT. Eligibility for EPP was then reassessed by the MARS 
virtual multidisciplinary team, which comprised a subset 
of the trial management group. This team was chaired by 
the chief investigator, coordinated by the trial team at the 
Institute of Cancer Research Clinical Trials and Statistics 
Unit (ICR-CTSU; Sutton, UK) and included the 
radiologist from the trial management group, the surgical 
coordinator, a medical and a radiation oncologist, and the 
designated MARS trial surgeon. For each patient deemed 
eligible by the referring clinical team, clinical data and 
imaging reports were circulated to MARS virtual 
multidisciplinary team members, and a teleconference 
CT scan to assess resectability
Fit for surgery (BTS guidelines) and postoperative 
radiotherapy and eligible for trial registration
Patient consent and registration
Histologically conﬁrmed mesothelioma
PET scan (recommended)
Mediastinoscopy
Eligible for MARS trial
Three cycles of platinum-based chemotherapy
Repeat staging by CT scan to assess resectability, 
nodal stage, and response to chemotherapy
Eligibility reviewed by MARS virtual 
multidisciplinary team
Patient consent
Randomisation
EPP surgery at specialist centre No EPP surgery
Postoperative radical 
hemithoracic radiotherapy
Continued oncological management and
follow-up and CT scan on ﬁrst relapse
Figure 1: Trial design
BTS=British Thoracic Society. MARS=Mesothelioma and Radical Surgery. 
EPP=extra-pleural pneumonectomy.
For the UK Thoracic Surgical 
Register see http://www.scts.
org/
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was held to provide a consensus on whether that patient 
should be oﬀ ered randomisation.
Study centres were also asked (but were not obliged) to 
complete a screening log of all patients with mesothelioma 
to document the eligible population and calculate the 
proportion who agreed to enter the registration phase of 
the study. Patients who fulﬁ lled eligibility criteria and 
who received chemotherapy outside of the trial, but in a 
manner consistent with the protocol, could also be 
registered for assessment of eligibility for randomisation 
by the MARS virtual multidisciplinary team.
MARS was approved by Cambridgeshire 4 Research 
Ethics Committee (MREC/04/5/008) and was locally 
approved at all participating centres.
Randomisation and masking
Patients were informed of the MARS virtual multi-
disciplinary team decision, and those still deemed eligible 
were invited to consent to be randomly assigned (1:1) to 
either EPP followed by radical radiotherapy or to no EPP. 
We used the TNM staging system proposed by the 
International Mesothelioma Interest Group.13 Patients 
were eligible for randomisation if they had completed 
preoperative chemotherapy and still had operable disease 
deﬁ ned as T1–3, N0–1, M0.
Registration and randomisation were done by telephone 
to the ICR-CTSU. The randomisation sequence was 
generated by computer at the ICR-CTSU, with permuted 
blocks of varying size and stratiﬁ cation by surgical centre. 
No investigator or patient had access to the randomisation 
sequence. Patients and investigators were not masked to 
treatment allocation.
Procedures
Patients assigned to EPP underwent surgery at one of 
the participating surgical centres in accordance with the 
trial surgical protocol (webappendix pp 1–2). Two surgical 
centres were designated initially because they had 
experienced surgeons who were used to undertaking 
EPP and whose results were audited. These centres 
remained the only surgical centres for much of the time 
MARS was open to recruitment. Three other centres 
were added later (Northern General Hospital, Sheﬃ  eld, 
and St James’s University Hospital, Leeds, opened to 
recruitment in 2006, but did not randomly assign an 
EPP patient until 2007), although in one there was no 
surgery within MARS. The surgeons at these centres 
also had experience of EPP, and their results had been 
audited. After surgery and providing the patient 
remained ﬁ t, postoperative radiotherapy was directed at 
the hemithorax (web ap pendix pp 3–5). All randomly 
assigned patients, including those in the no EPP group, 
received continued oncological management according 
to local policy, which could include chemotherapy, 
palliative radiotherapy, or further surgery.
We monitored acute and late radiotherapy eﬀ ects 
(deﬁ nded in the webappendix p 5), and collected clinical 
follow-up data including quality-of-life assessment by 
the European Organisation for Research and Treatment 
of Cancer (EORTC) QLQ-C30 and QLQ-LC13 
questionnaires at registration, randomisation, 6 weeks, 
3, 6, 9, 12, 18 (quality of life only), and 24 months, and 
annually thereafter.
The aim of the MARS feasibility study was to quantify 
the proportion of eligible patients subsequently 
randomised, to assess the feasibility of randomising 
50 patients within 1 year,11 and to measure clinical 
outcomes in randomly assigned patients. Endpoints 
included the proportion randomised to EPP who 
completed trimodal therapy; perioperative mortality 
(deﬁ ned for the purposes of referral to the independent 
112 (57) patients registered
  55 registrations not completed
        27 disease progression
        18 patient withdrawal
          5 inoperable
          4 other
          1 died
  57 reviewed by MDT
        7 excluded 
           6 disease progression
           1 patient withdrawal
  50 (24) randomised
257 (246) patients’ screening logs received
149 patients not approached
         106 ineligible
           30 clinical decision
           12 other
             1 unknown
108 (97) patients approached
40 patients not registered
       18 ineligible
         3 clinical decision
      18 patient decision
         1 other (no radiological staging)
  68 (57) patients registered
  24 (13) randomly assigned 
  to EPP (with radical radiotherapy)
  26 (11) randomly assigned 
  to no EPP
  44 patients registered
Screening logs not received
Figure 2: Feasibility of registration and recruitment to MARS
Numbers in brackets indicate those patients screened who did not have chemotherapy before registration. 
MARS=Mesothelioma and Radical Surgery. MDT=multidisciplinary team. EPP=extra-pleural pneumonectomy.
See Online for webappendix
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monitoring committee for review as a death occurring 
during surgery, up to 30 days thereafter, or in a patient 
who was never discharged from hospital after the 
operation); quality of life; overall survival; progression-
free or relapse-free survival, deﬁ ned as time from 
randomisation to progression (no EPP patients) or 
relapse (EPP patients); or death from any cause. Deaths 
were reviewed by the independent data monitoring 
committee for relatedness to trial treatment.
Statistical analysis
The main analyses of the MARS feasibility study were 
descriptive and included summary information from the 
screening logs on reasons for loss or withdrawal, the 
proportions of eligible patients registered and randomly 
assigned to treatment, and the proportion of randomly 
assigned patients who completed EPP surgery. We also 
assessed treatment compliance, complications, peri-
operative mortality and quality of life.
All analyses of randomly assigned patients were by 
intention to treat and were censored at the date last 
known to be alive. Survival rates were compared by the 
exact log-rank test because of the small patient numbers. 
HRs and 95% CIs were calculated by Cox proportional 
hazards regression, adjusting for the prespeciﬁ ed 
prognostic factors of sex, histological subtype, stage at 
randomisation, and age at randomisation. HRs less 
than 1·0 favoured EPP. We used the reverse Kaplan-
Meier method to calculate median follow-up. All 
proportions are reported with two-sided 95% CIs. All 
analyses were done with Stata (version 10.1).
During the trial, safety and eﬃ  cacy data were reviewed 
regularly by the independent data monitoring committee. 
Perioperative mortality was monitored by a group 
sequential approach with the potential for the independent 
data monitoring committee to advise on trial closure 
should a stopping boundary be crossed. This trial is 
registered, number ISRCTN95583524.
Overall cohort 
(n=112)
Patients 
subsequently 
randomised 
(n=50) 
Sex (male) 101 (90%) 46 (92%) 
Age at registration (years) 61·7 (5·3) 61·5 (4·4) 
WHO performance status score
0 34 (30%) 19 (38%) 
1 68 (61%) 28 (56%) 
Unknown 10 (9%) 3 (6%) 
Method of histological diagnosis
Abram’s needle or blind biopsy 2 (2%) 0 (0%) 
CT or ultrasound guided 27 (24%) 10 (20%) 
Surgical 76 (68%) 38 (76%) 
Other* 3 (3%) 2 (4%) 
Unknown 4 (4%) 0 (0%) 
Histological subtype
Epithelioid 83 (74%) 40 (80%) 
Sarcomatoid 3 (3%) 0 (0%) 
Mixed or biphasic 12 (11%) 7 (14%) 
Unknown on ﬁ rst relapse 14 (13%) 3 (6%) 
Data are number (%) or mean (SD). Percentages do not sum to 100 in some cases 
because of rounding. *Aspiration cytology (n=1), cytology (tumour block; n=1), 
and pleural eﬀ usion (n=1).
Table 1: Patient characteristics at registration
EPP (n=24) No EPP (n=26)
Sex (male) 23 (96%) 23 (88%)
Age group at registration (years)  
<45 0 (0%) 0 (0%)
45–54 2 (8%) 2 (8%)
55–64 17 (71%) 19 (73%)
65–74 5 (21%) 5 (19%)
WHO performance status score at randomisation
0 13 (54%) 10 (38%)
1 11 (46%) 15 (58%)
Missing 0 (0%) 1 (4%)
Method of histological diagnosis
Abram’s needle or blind biopsy 0 (0%) 0 (0%)
CT or ultrasound guided 4 (17%) 6 (23%)
Surgical 20 (83%) 18 (69%)
Other* 0 (0%) 2 (8%)
Unknown 0 (0%) 0 (0%)
Histological subtype
Epithelioid 20 (83%) 20 (77%)
Sarcomatoid 0 (0%) 0 (0%)
Mixed or biphasic 3 (13%) 4 (15%)
Unknown 1 (4%) 2 (8%)
Stage* at randomisation
T1, N0, M0 3 (13%) 4 (15%)
T2, N0, M0 12 (50%) 12 (46%)
T2, N1, M0 0 (0%) 1 (4%)
T3, N0, M0 9 (38%) 8 (31%)
T3, N1, M0 0 (0%) 1 (4%)
Chemotherapy received†
Cisplatin and gemcitabine 10 (42%) 10 (38%)
Cisplatin and pemetrexed 8 (33%) 8 (31%)
Mitomycin, vinblastine, and cisplatin 6 (25%) 5 (19%)
Cisplatin and vinorelbine 0 (0%) 3 (12%)
Change in tumour stage during chemotherapy
Responded 3 (13%) 2 (8%)
Stable 15 (63%) 19 (73%)
Progressed 3 (13%) 4 (15%)
Missing 3 (13%) 1 (4%)
Data are number (%). Percentages do not sum to 100 in some cases because of 
rounding. EPP=extra-pleural pneumonectomy. *Combination of the staging 
results by CT scan, PET scan, and mediastinoscopy. †Clinicians were free to 
choose the chemotherapy regimen as long as it included a platinum-based drug.
Table 2: Characteristics of patients subsequently randomly assigned to 
EPP or no EPP
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Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between Oct 1, 2005 and Nov 3, 2008, 112 patients were 
registered, of whom 50 were subsequently randomly 
assigned to EPP (n=24) or to no EPP (n=26; ﬁ gure 2). For 
this analysis, all treatment data were included up to 
Nov 23, 2009; outcome data were included up to 
April 19, 2010. The median time between registration and 
randomisation was 3·6 months (IQR 2·8–4·3). Median 
follow-up from randomisation, in all patients, was 
24·7 months (IQR 21·6–32·2). 62 patients (55·4%) did 
not proceed to random allocation, mainly because of 
disease progression (33 patients), inoperability (ﬁ ve 
patients), or patient choice (19 patients).
12 centres submitted screening logs for 257 patients. 
Figure 2 shows the numbers of patients registered and 
subsequently randomly assigned to treatment among 
those who were screened. Of the 246 who were screened 
before any chemotherapy, 97 (39·4%, 95% CI 33·1–45·7) 
were invited to enter the registration phase, 57 (23·2%, 
18·0–28·8) were registered, and 24 (9·8%, 6·4–14·2) 
were subsequently randomised. 136 of 257 (53%) patients 
were excluded for clinical reasons (ineligibility, clinical 
decision, disease progression, and inoperability) before 
the patient was approached, 21 of 108 (19%) were excluded 
before registration, and 39 of 112 (35%) were excluded 
before randomisation. These data suggest an unavoidable 
cumulative loss of 76·3% (95% CI 70·6–81·3) 
independent of patient withdrawal or other reasons.
During the recruitment period an increasing number 
of patients were referred to MARS centres for assessment 
for eligibility. 44 patients were registered in this way, 
bypassing the screening log process, and therefore came 
from an unknown denominator.
Table 1 shows patient characteristics at registration for 
all 112 registered patients and the 50 who were 
subsequently randomised. 83 (74%) of 112 registered 
patients received three cycles of chemotherapy. Seven 
patients had more than three cycles, two of whom were 
deemed eligible by the MARS virtual multidisciplinary 
team and subsequently randomly assigned, and four 
patients had fewer than three cycles of chemotherapy, one 
of whom was subsequently randomly assigned. 18 patients 
(16%) did not receive any chemotherapy, most frequently 
because of disease progression, and were thus ineligible 
for random allocation. The most common chemotherapy 
regimen given was cisplatin and gemcitabine (38 of 94; 
40%), followed by cisplatin and pemetrexed (24; 26%), 
and mitomycin, vinblastine, and cisplatin (20; 21%).
38 (76%) of 50 patients subsequently randomly assigned 
to EPP (n=18) or no EPP (n=20) had PET-CT scan 
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      1 reoperation plus cardiac plus 
pulmonary
      1 cardiac plus pulmonary plus 
infection
      1 cardiac plus pulmonary*
      1 cardiac plus urine retention
      2 pulmonary plus other†
      1 reoperation*
      1 cardiac
      3 other‡
  8 received radical radiotherapy
3 EPP surgery abandoned
    1 perioperative death
    2 unexpected disease progression
8 radical radiotherapy not received
    1 clinical decision
    2 toxicity
    2 disease progression
    3 died
Figure 3: Feasibility of EPP surgery and radical radiotherapy treatment
EPP=extra-pleural pneumonectomy. *Subsequent perioperative death. †Other 
complications were ﬂ exible bronchoscopy or drain infection in 
pneumonectomy cavity; ischaemic right leg requiring femoropopliteal bypass 
and eventual below knee amputation with culture-positive pneumonia needing 
mini tracheostomy. ‡Postoperative pain, low blood pressure, and intraoperative 
bleeding and further bleeding from chest drains postoperatively.
Figure 4: Overall survival
EPP=extra-pleural pneumonectomy.
Articles
768 www.thelancet.com/oncology   Vol 12   August 2011
information available for the MARS virtual multi-
disciplinary team. PET-CT scan results suggested that 
23 patients (ten EPP and 13 no EPP) were resectable, ﬁ ve 
(four EPP and one no EPP) were equivocal, and in ten 
patients (four EPP and six no EPP) this information was 
not available. Table 2 shows the characteristics of the 
50 patients at random allocation. No diﬀ erences in terms 
of stage or other patient-related features were noted 
between the two groups.
Of the 24 patients randomly assigned to EPP, ﬁ ve did not 
proceed to surgery: three by patient choice and two by 
clinician decision (ﬁ gure 3). EPP was started in 19 patients 
but in two patients with unexpected disease progression 
EPP was not completed and one patient died during 
surgery. Thus, 16 patients completed EPP surgery (ﬁ gure 3). 
Four surgeons did the EPP operations: two were assigned 
ten each before randomisation, one assigned three, and 
one assigned one. If the patient was not randomly assigned 
to receive surgery or declined, the surgeon did not do an 
EPP. There were two further deaths within the protocol-
deﬁ ned perioperative period, giving a total of three 
perioperative deaths in 24 (12·5%, 95% CI 2·7–32·4) in 
patients randomised to EPP by intention to treat and three 
perioperative deaths in 19 (15·8%, 3·4–39·6) patients in 
whom EPP was attempted. 11 of 16 patients who were 
assigned to and completed EPP surgery had at least one 
postoperative complication (ﬁ gure 3).
Eight of the 16 patients who completed EPP received 
radical radiotherapy, ﬁ ve of whom had complications. 
Severe (grade 3 or 4) acute radical radiotherapy side-
eﬀ ects were rare: two patients had grade 3 fatigue and 
one had grade 3 pain. Severe late side-eﬀ ects were fatigue 
(n=1, grade 3), pneumonitis or dyspnoea (n=2, grade 3), 
and ascites (n=1, grade 3). One patient developed 
paraplegia 42 days after completion of radiotherapy; this 
patient had MRI and clinical features of herpes myelitis 
(grade 4). This patient also had coexisting herpes retinitis 
and progressive diﬀ use changes on MRI of the spinal 
cord outside the irradiated region and thus the diagnosis 
of radiation-induced myelopathy was excluded. The 
patient was still paraplegic with no evidence of recurrence 
2·3 years after multimodal treatment.
Six patients allocated to EPP received additional 
oncological management. Of these, two had completed 
EPP surgery and none received radical radiotherapy. One 
patient whose EPP operation was not started received 
further chemotherapy. One patient whose EPP operation 
was abandoned received radiotherapy. In two patients a 
decision to do lung-sparing debulking or pleurectomy 
surgery was taken during the operation. Two patients 
who had completed EPP operation had further surgery to 
deal with thoracic space infection.
16 of the 26 patients randomly assigned to no EPP 
received further oncological management: one received 
radiotherapy alone; seven had further chemotherapy 
alone; one had EPP surgery oﬀ  trial; one had radiotherapy 
and chemotherapy; one had radiotherapy and non-EPP 
surgery; two had chemotherapy and EPP surgery oﬀ  trial; 
one had chemotherapy and cediranib (as part of a phase 1 
trial); and two had radiotherapy, chemotherapy, and non-
EPP surgery. Thus, three patients had EPP oﬀ  trial, 
13 had further chemotherapy, ﬁ ve had some form of 
radiotherapy, three had non-EPP surgery, and ten received 
no further treatment.
At a median follow-up from randomisation of 
24·7 months (IQR 21·6–32·2), 30 of 50 patients had died 
(EPP n=17; no EPP n=13); four of these deaths (three in the 
EPP group and one in the no EPP group) occurred more 
than 18 months after randomisation. 25 deaths were due to 
mesothelioma (EPP n=13; no EPP n=12), one (EPP) was 
due to respiratory failure before relapse, and four were 
perioperative (EPP n=3; no EPP n=1). Of the perioperative 
deaths in patients randomly assigned to EPP, one had a 
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rupture of the aortic isthmus (multiple sites) and died on 
the operating table; one died at home (cause unknown) 
shortly after a further operation to have a diaphragm patch 
repaired; and one died of bronchopneumonia 6 weeks after 
the EPP operation. The perioperative death in the no EPP 
group was one of the patients who underwent EPP surgery 
outside the trial; the patient died of multiple organ failure.
12-month survival was 52·2% (95% CI 30·5–70·0) in 
those allocated EPP and 73·1% (51·7–86·2) in those 
allocated to no EPP (diﬀ erence 18·0%, –1·8 to 43·9; 
ﬁ gure 4). The hazard ratio for overall survival in the 
EPP group (unadjusted) versus the no EPP group 
was 1·90 (95% CI 0·92–3·93; exact p=0·082). After 
adjust ment for prespeciﬁ ed prognostic factors the HR 
was 2·75 (1·21–6·26; p=0·016). Median survival from 
randomisation for patients allocated to EPP was 
14·4 months (5·3–18·7). For patients randomised to no 
EPP, median survival was estimated to be 19·5 months 
(13·4 to time not yet reached). None of the three long-
term survivors allocated to no EPP crossed over 
to EPP.
42 of 50 patients (EPP n=19, no EPP n=23; four from 
the no EPP group had an event more than 18 months 
after random allocation) had disease recurrence (EPP 
group), progression (no EPP group), or died before 
relapse or progression (ﬁ gure 5). 12-month recurrence-
free survival in the EPP group was 34·8% (95% CI 
16·6–53·7) and median recurrence-free survival was 
7·6 months (5·0–13·4). 12-month progression-free 
survival in the no EPP group was 42·3% (23·5–60·0) and 
median progression-free survival was estimated to be 
9·0 months (7·2–14·7).
23 patients in the EPP group and 26 in the no EPP 
group consented to quality-of-life assessment and 12 and 
19 patients completed the quality-of-life questionnaires, 
respectively. Median quality-of-life scores seemed to be 
lower for the EPP group than the no EPP group, with the 
lowest median score shortly after surgery (ﬁ gure 6); 
however, there were no statistically signiﬁ cant diﬀ erences 
between treatment groups.
12 serious adverse events were reported during the 
study period: ten in the EPP group and two in the no 
EPP group. Three were suspected unexpected serious 
adverse reactions (two in the EPP group and one in the 
no EPP group), eight were serious adverse reactions (all 
in the EPP group), and there was one other serious 
adverse event in the no EPP group.
Discussion
In an intention-to-treat analysis of outcome data in the 
MARS trial, we noted no survival advantage for the EPP 
surgery group compared with the no EPP group. 
Furthermore, when adjusted for prognostic variables, 
patients allocated to no EPP had a better outcome than 
those allocated to EPP. No signiﬁ cant diﬀ erences between 
groups were reported in the quality-of-life analyses. In 
summary, the outcomes of MARS provide no evidence of 
beneﬁ t from EPP within trimodal therapy over 
chemotherapy alone, for survival or quality of life.
Survival data for EPP were provided in a recent systematic 
review,14 which allows us to put the EPP survival data from 
MARS in context (panel). For 30 studies where data were 
given, 12-month survival ranged from 36% to 83%, with an 
overall survival of 57·1% (1231 of 2155 patients) compared 
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with 52·2% in the MARS EPP arm. For 35 studies that 
included 2314 patients, median survival ranged from 4 to 
35 months, with a median of 14·5 months. A subset of 
four of these studies15–18 plus an EORTC phase 2 trial19 are 
most comparable with MARS in that patients were all 
operated on since 2000, had similar stage criteria for EPP, 
and were planned for trimodal therapy in the same 
sequence, starting with chemotherapy with subsequent 
EPP and then radiotherapy (table 3). Median survival by 
intention to treat ranged from 14 to 25·5 months. In 
studies in which chemotherapy was the ﬁ rst modality, the 
survival time was counted from the start of chemotherapy15–18 
or from registration.19 In MARS, survival was calculated 
from the later timepoint of randomisation to EPP or no 
EPP (median 3·6 [IQR 2·8–4·3] months between 
registration and randomisation). Thus, to make any 
comparison, 3·6 months would have to be added to the 
14·4 months median survival in the EPP group of MARS 
and the resulting estimated 18 months survival from the 
start of treatment becomes similar to these reported 
series (table 3).
We cannot know from these non-controlled studies 
what survival might have been for similar patients to 
those having EPP but who were managed without surgery. 
The median survival for no EPP in MARS was 19·5 months 
from randomisation, which is after completion of 
chemotherapy. This is comparable with patients who 
received trimodal therapy (table 3), particularly if the 
discounted 3·6 months from registration to randomisation 
is taken into account. Overall survival for the no EPP 
group in MARS was better than that used in the power 
calculations for the proposed phase 3 trial, for which 
670 patients would be needed on the basis of the power 
calculation.9 In any subsequent planned phase 3 study of 
extirpative surgery, this non-surgical outcome would have 
to be taken into consideration in the power calculations of 
the number of patients needed overall to show superiority 
in the surgical arm.
Morbidity is diﬃ  cult to compare between arms with 
two very diﬀ erent approaches to management but for 
EPP morbidity has been consistently reported as high19–21 
and MARS was no exception. In MARS, no signiﬁ cant 
diﬀ erences were reported in the quality-of-life analyses 
between groups; however, there seemed to be poorer 
quality of life, particularly just after surgery in patients 
randomly assigned to EPP. This ﬁ nding shows that any 
surgical group inevitably has more impaired quality of 
life in the ﬁ rst few weeks after surgery compared with a 
non-surgical group. The same consideration applies to 
any protocol that includes radical radiotherapy.
In MARS, most patients randomly assigned to EPP had 
surgery in two centres with considerable experience in 
the surgery and perioperative care of these patients. Late 
in the course of the study, two further surgical centres 
were approved to do EPP within MARS. No postoperative 
deaths occurred at these additional centres. The 30-day 
mortality rate was 10·5% (two of the 19 patients for whom 
Panel: Research in context
Systematic review
In 2004, we did a systematic review to assess the available 
evidence for eﬀ ectiveness of extra-pleural pneumonectomy 
(EPP).8 We identiﬁ ed seven publications of multimodal 
therapy but all were analysed on the basis of completed 
treatment, oﬀ ered no control data, and whether the most 
optimistic estimate of eﬀ ect size was suﬃ  cient to outweigh 
the burden of treatment was debatable. During 
presentations of the available data to meetings at the British 
Thoracic Society and Society for Cardiothoracic Surgery in 
Great Britain and Ireland and in an editorial in the 
British Medical Journal9 we conﬁ rmed the uncertainty 
regarding the eﬀ ectiveness of EPP was suﬃ  cient to propose a 
randomised controlled trial.
Interpretation
In the Mesothelioma and Radical Surgery (MARS) 
feasibility study, patients randomly assigned to no EPP 
had better median and 1-year survival than those assigned 
to EPP. When compared with survival data from EPP in a 
systematic review,14 the MARS surgical outcomes are in the 
middle of the reported range of median and 1-year 
survival rates. The no EPP group in MARS survived longer 
than the historical life expectancy estimates with which 
EPP results are reported in uncontrolled studies. In MARS, 
survival was reported from randomisation to EPP, which 
was after completion of three cycles of chemotherapy 
rather than from first chemotherapy as is customarily 
done for reports of EPP within trimodal therapy. An 
allowance for this difference in starting time puts the 
survival of the patients in the no EPP group in the upper 
part of the range of reported trimodal therapy outcomes. 
The evidence from MARS, in the context of external 
evidence from observational studies, suggests that the net 
effect of EPP is to shorten survival without a gain in 
quality of life. Lung-sparing surgery is associated with 
better outcomes than EPP13 but survival cannot be 
assumed to be better than it would have been without any 
extirpative surgery. A con trol led trial of lung sparing 
surgery is needed.
Start End Stage Epithelioid 
histology 
(n/N)
Treatment Number 
intended 
to treat
Median 
survival 
(intention to 
treat; months)
Weder,15 2007 2000 2003 T1–3, N0–2, M0 42/61 C, EPP, RT 61 19·8*
Rea,16 2007 2000 2003 T1–3, N0–2, M0 20/21 C, EPP, RT 21 25·5*
Krug,17 2009 2003 2006 T1–3, N0–2, M0 62/77 C, EPP, RT 77 16·8*
De Perrot,18 2009 2001 2007 T1–3, N0–2, M0 44/60 C, EPP, RT 60§ 14*
Van Schil,19 2010 2005 2007 T1–3, N0–2, M0 31/58 C, EPP, RT 58 18·4†
EPP=extra-pleural pneumonectomy. TMT=trimodal therapy. C=chemotherapy. RT=radiotherapy. *Counted from 
ﬁ rst chemotherapy. †Counted from registration. 
Table 3: Reports of EPP within trimodal therapy
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surgery with intention to perform EPP was started). One 
further patient died from pneumonia 6 weeks 
postoperatively. In the systematic review of results of EPP 
in 34 studies,14 including 2320 patients, 30-day mortality 
ranged from 0% to 11·8% and was 6·0% overall. For the 
993 patents in 14 studies that were reported since 2008 
when MARS closed, and which therefore represent a 
similar era to when patients were recruited to MARS, 
mortality was 5·6% (range 0–11·1%).14 One should note, 
however, that for a hypothetical study of 20 consecutive 
operations, an anticipated 5% mortality would shift to 
10% or 0% with one additional or one fewer death. 
Whether a death is recorded at 29 or 31 days would also 
make a disproportionately large diﬀ erence to the results. 
In small series, such data are inherently unstable. In any 
future randomised phase 3 study of mesothelioma 
surgery, as many thoracic surgical centres as possible 
would need to be involved. In doing so, a rigorous method 
of surgical quality assurance would be important.
At the time MARS was being planned, pemetrexed was 
not yet the standard of care in the UK. The chemotherapy 
regimen for each patient was selected from the suggested 
regimens by the treating centre. During recruitment, the 
chemotherapy standard of care for mesothelioma 
changed, and patients recruited later were more likely to 
receive cisplatin and pemetrexed than those recruited 
earlier in the study. There was no imbalance in the use of 
pemetrexed between the EPP and no EPP arms.
The challenges of compliance with the trial protocol in 
this study should be taken into account when planning 
future phase 3 studies in which there is a large diﬀ erence 
in treatments between the two arms. Despite having 
given informed consent to random allocation, some 
patients allocated to the no EPP group decided to pursue 
a radical surgery approach outside the trial. Some patients 
did not undergo surgery because, when reassessed after 
chemotherapy and when the risk:beneﬁ t balance of EPP 
had been explained by the operating surgeon, they opted 
not to proceed. Some patients had become inoperable 
during the time from initial assessment to reassessment. 
Nonetheless, although only 50 patients were randomised 
over the entire study period, rather than in the anticipated 
year, the fact that recruitment of these patients was 
possible suggests that the expected reluctance of patients 
to accept no radical surgery in a study with two very 
diﬀ erent treatment approaches to management of 
mesothelioma was not as marked as had been expected.
To our knowledge, MARS is the ﬁ rst study to 
successfully randomly assign patients to EPP and no 
radical surgery for mesothelioma. The MARS trial was 
rigorously done, with the ﬁ nal decision that a patient was 
eligible for randomisation within MARS made in 
discussions by the MARS virtual multidisciplinary team 
and the allocation to EPP or no EPP made within the 
ICR-CTSU. The accumulating outcome data were held at 
the trial centre and were only shared with the independent 
data monitoring committee. Although the study is small 
and the conclusions must be guarded, we believe the 
ﬁ ndings are of relevance to guide practice.
The median survival after EPP within MARS is 
consistent with 10, 12, 13, and 14 months in larger 
observational studies,22–25 as was the proportion of 
complications. However, a much larger study with 
longer follow-up would be needed to provide reliable 
evidence on mortality patterns and long-term survival 
for any extirpative surgery for mesothelioma whether 
EPP or lung-sparing surgery. A trial assessing the 
potential beneﬁ ts of total pleurectomy might be more 
practical in the future management of mesothelioma 
given the lower risk of perioperative mortality and 
morbidity in an ageing population with increasing 
comorbidities. On the basis of the results of MARS, a 
further study is being developed that does not include 
EPP as the recommended surgery. Recent data that 
compared lung-sparing total pleurectomy and 
decortication with EPP support the contention that this 
approach is unlikely to result in poorer survival than 
that associated with EPP in mesothelioma.22
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